CytomX Therapeutics stock closed at USD 2.28, down 5.39 percent on October 16

Published on 10/17/2026 at 22:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CytomX Therapeutics stock closed at USD 2.28 on October 16, 2026, down 5.39 percent. Cantor Fitzgerald kept a USD 12.00 target on October 13, 2026.

Trading levels and upcoming dates

The Nasdaq session fell 5.39 percent on October 16, 2026.
Cantor Fitzgerald maintained a USD 12.00 target on October 13, 2026.
CytomX Therapeutics stock closed at USD 2.28 on October 16, 2026 at 4:00 p.m. ET, down 5.39 percent versus USD 2.41.
CytomX Therapeutics is estimated to report third-quarter results on November 5, 2026.

CTMX, US23284F1057, Illustration mit AI erstellt.

CytomX Therapeutics stock closed at USD 2.28 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 5.39 percent from USD 2.41. The decline leaves the clinical-stage biotechnology company near its 52-week low of USD 2.20.

On October 13, 2026, Investing.com reported that Cantor Fitzgerald reiterated an Overweight rating and a USD 12.00 price target for CytomX. The target is more than five times the October 16 closing price, while the firm highlighted the company's clinical programs and prospective 2027 development milestones.

Second-quarter revenue fell sharply

CytomX reported USD 1.42 million in revenue for the second quarter of 2026, down from USD 10.26 million in the first quarter. Net loss widened to USD 20.67 million from USD 18.25 million, while diluted earnings per share were negative USD 0.09 compared with negative USD 0.10 in the first quarter. These figures come from the standardized quarterly statements for the period ended June 30, 2026.

Price stays near yearly low

The October 16 Nasdaq session traded between USD 2.26 and USD 2.44, with volume of 2,828,147 shares against an average of 3,334,931. The 52-week range was USD 2.20 to USD 8.21, placing the close 3.64 percent above the low and 72.23 percent below the high.

Valuation and reporting date

CytomX had a market capitalization of USD 496.8 million on October 16, 2026. Its price-to-earnings ratio was negative 5.07, and its trailing dividend yield was 0.00 percent. MarketBeat estimated the next quarterly report for November 5, 2026, before the market opens, with consensus revenue of USD 10.38 million and consensus earnings per share of negative USD 0.09.

Comparison with peers

CytomX Therapeutics (Nasdaq, USD): minus 5.39 percent, P/E -5.07, market capitalization USD 496.8 million.

Alto Neuroscience (Nasdaq, USD): minus 3.01 percent, P/E -8.85, market capitalization USD 861.0 million.

Fate Therapeutics (Nasdaq, USD): minus 7.01 percent, P/E -1.70, market capitalization USD 208.6 million.

Nasdaq closing context

CytomX is headquartered in South San Francisco and develops conditionally activated antibody-based cancer therapies through its Probody platform. The company has strategic collaborations with larger pharmaceutical groups, making clinical progress and partnership payments important variables alongside quarterly revenue.

The Nasdaq was closed on October 17, 2026, so the latest completed session remains the October 16 close. CytomX Therapeutics closed at USD 2.28 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 5.39 percent versus the prior Nasdaq close of USD 2.41.